NathanHawkeyMDMBA

Clinical Fellow, Hematology and Oncology Duke University

Dr. Hawkey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Duke University HospitalFellowship, Hematology and Medical Oncology, 2019 - 2023
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2017 - 2019
Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 2016 - 2017
Tulane University Freeman School of BusinessMBA, 2015 - 2016
Tulane University School of MedicineClass of 2016
University of Colorado BoulderBA, Chemistry, 2004 - 2009

PubMed

9 citations
The Value of Phenotypic Precision Medicine in Prostate Cancer.
Nathan M Hawkey, Amanda Broderick, Daniel J George, Oliver Sartor, Andrew J Armstrong
The Oncologist. 2023-02-08
A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer.
Kathryn E Ware, Beatrice C Thomas, Pelumi D Olawuni, Maya U Sheth, Nathan Hawkey
Frontiers in Molecular Biosciences. 2023-01-01
12 citations
Loss of ATRX promotes aggressive features of osteosarcoma with increased NF-κB signaling and integrin binding.
Suzanne Bartholf DeWitt, Sarah Hoskinson Plumlee, Hailey E Brighton, Dharshan Sivaraj, E J Martz
JCI Insight. 2022-09-08

Journal Articles

A Zebrafish Model of Metastatic Colonization Pinpoints Cellular Mechanisms of Circulating Tumor Cell Extravasation
Tyler Allen, Mark M Cullen, Hiroyuki Mochizuki, Nathan Hawkey, Lan Nguyen, Elyse Schechter, Luke Borst, Jeffrey A Yoder, Jennifer Freedman, Steven R Patierno, Ke Cheng..., Front. Oncol., 9/23/2021